Table 1 Clinical information on PBMC and plasma sample donors.

From: Enhanced influenza A H1N1 T cell epitope recognition and cross-reactivity to protein-O-mannosyltransferase 1 in Pandemrix-associated narcolepsy type 1

  PBMC Plasma
  NT1 patients (all) NT1 patients (Discovery cohort) NT1 patients (Validation cohort) Healthy controls NT1 patients Healthy vaccinated controls Healthy unvaccinated controls
Number of subjects 28 20 14 33 47 57 130
Vaccinated with Pandemrix (%) 100 100 100 100 100 100 0
Age at vaccination (years), median (range) 11.5 (5.1–20.9) 11.1 (5.1–20.9) 11.5 (6.9–18.6) 8.5 (4.1–16.4) 11.7 (4.4–16.6) 7.5 (0.9– 14.8) n/a
Age at vaccination (years), mean 11.8 11.1 12.5 9.0 11.4 8.3 n/a
Age at sampling (years), median (range) 15.1 (7.7–23.1) 13.4 (7.7–23.1) 15.4 (10.9–23.1) 9.8 (5.5–18.7) 13.0 (5.9–17.9) 9.0 (1.4–16.5) 11.0 (4.0–18.0)
Time between vaccination and sampling (days), median 1078 805 1640 527 550 516 n/a
HLA DQB1*06:02 genotype, N (%) 28 (100) 21 (100) 14 (100) 14 (42.4) 47 (100) 21 (36.8) 68 (52.3)
Gender, female, N (%) 18 (64.3) 11 (52.4) 9 (64.2) 19 (57.6) 28 (59.6) 30 (52.6) 61 (46.9)